A clinical trial of fibroblast transplantation for the treatment of mucopolysaccharidoses.
This paper reports the clinical and biochemical results in six patients with Hurler disease (Mucopolysaccharidosis IH; McKusick 25280), two patients with Hunter disease (Mucopolysaccharidosis II; McKusick 25285) and one patient with Sanfilippo B disease (Mucopolysaccharidosis IIIB; McKusick 25292) who were treated by fibroblast transplantation. Except for one patient who died for a coincidental reason, the patients have been studied for between 2.5 and 4.5 years. The clinical course of the disease was not materially altered. There was no evidence that the patients had developed immune responses against the transplanted fibroblasts. Transplantation did not produce measurable levels of either alpha-L-iduronidase (EC 3.2.1.76) in the leukocytes from patients with Hurler disease or of N-acetyl-alpha-D-glucosaminidase (EC 3.2.1.50) in the plasma of the patients with Sanfilippo B disease. Under the conditions used for the assay, leukocytes from the patients with Hunter disease had detectable levels of residual alpha-L-idurono-2-sulphate sulphatase activity which were increased after the transplants, although these changes were of inconstant size and their time course was not consistently related to the transplantations. Cytogenetic studies in cases where the donor was of the opposite sex detected only cells of the recipient's sex among the fibroblasts grown from biopsies of the transplantation sites. The technique used would have detected a donor to recipient cell ratio of 1:100. We found no consistent long-term trends in the excretion patterns of glycosaminoglycans and oligosaccharides from either a quantitative or qualitative point of view which could be specifically related to the transplantation. The combined administration of immunosuppressive doses of prednisolone and azathioprine was associated with an increased excretion of the lower molecular weight glycosaminoglycans. We conclude that fibroblast transplantation is not therapeutically useful in the diseases studied.
D000118:Acetylglucosaminidase / Q000032:analysis; D002675:Child, Preschool; D002871:Chromosome Banding; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic; D005260:Female; D005347:Fibroblasts / Q000637:transplantation*; D006025:Glycosaminoglycans / Q000652:urine; D006801:Humans; D007066:Iduronate Sulfatase / Q000032:analysis; D007068:Iduronidase / Q000032:analysis; D007165:Immunosuppression Therapy; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008970:Molecular Weight; D009083:Mucopolysaccharidoses / Q000235:genetics / Q000628:therapy*; D009844:Oligosaccharides / Q000652:urine; D001616:beta-Galactosidase / Q000032:analysis
D006025:Glycosaminoglycans; D009844:Oligosaccharides; D007066:Iduronate Sulfatase; D001616:beta-Galactosidase; D000118:Acetylglucosaminidase; D007068:Iduronidase